This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Oxaloacetic acid
DrugBank Accession Number
DB16921
Background

Not Available

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 132.071
Monoisotopic: 132.005873229
Chemical Formula
C4H4O5
Synonyms
  • 2-oxobutanedioic acid
  • Anhydrous enol-oxaloacetate
  • Bioepg
  • Ketosuccinic acid
  • Oxalacetic acid
  • Oxalacetic acid trans-(z)-enol form
  • Oxaloacetate
  • Oxosuccinic acid
External IDs
  • NSC-77688
  • OAA

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
2F399MM81J
CAS number
328-42-7
InChI Key
KHPXUQMNIQBQEV-UHFFFAOYSA-N
InChI
InChI=1S/C4H4O5/c5-2(4(8)9)1-3(6)7/h1H2,(H,6,7)(H,8,9)
IUPAC Name
2-oxobutanedioic acid
SMILES
OC(=O)CC(=O)C(O)=O

References

General References
Not Available
RxNav
1661329

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Not Yet RecruitingTreatmentGlioblastoma Multiforme (GBM)1
2RecruitingSupportive CareAnatomic Stage 0 Breast Cancer AJCC v8 / Anatomic Stage 1 Breast Cancer AJCC v8 / Anatomic Stage IA Breast Cancer AJCC v8 / Anatomic Stage IB Breast Cancer AJCC v8 / Anatomic Stage II Breast Cancer AJCC v8 / Anatomic Stage IIA Breast Cancer AJCC v8 / Anatomic Stage IIB Breast Cancer AJCC v8 / Anatomic Stage IIIA Breast Cancer AJCC v8 / Early Stage Breast Carcinoma / Prognostic Stage 0 Breast Cancer AJCC v8 / Prognostic Stage 1 Breast Cancer AJCC v8 / Prognostic Stage 2 Breast Cancer AJCC v8 / Prognostic Stage IA Breast Cancer AJCC v8 / Prognostic Stage IB Breast Cancer AJCC v8 / Prognostic Stage IIA Breast Cancer AJCC v8 / Prognostic Stage IIB Breast Cancer AJCC v8 / Prognostic Stage IIIA Breast Cancer AJCC v81
2, 3CompletedTreatmentParkinson's Disease (PD)1
1CompletedTreatmentAlzheimer's Disease (AD)1
1Not Yet RecruitingTreatmentMyasthenia Gravis1
1RecruitingTreatmentAmyotrophic Lateral Sclerosis (ALS)1
Not AvailableCompletedBasic ScienceAlzheimer's Disease (AD)1
Not AvailableCompletedTreatmentPremenstrual Syndrome (PMS)1
Not AvailableEnrolling by InvitationTreatmentChronic Fatigue Syndrome/ Myalgic Encephalitis (CFS/ME) / Fatigue1
Not AvailableRecruitingTreatmentCoronavirus Disease 2019 (COVID‑19) / Treatment of Fatigue After Resolution of COVID-19 Infection1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility57.1 mg/mLALOGPS
logP-0.68ALOGPS
logP-0.042Chemaxon
logS-0.36ALOGPS
pKa (Strongest Acidic)2.41Chemaxon
pKa (Strongest Basic)-9.9Chemaxon
Physiological Charge-2Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area91.67 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity24.33 m3·mol-1Chemaxon
Polarizability10.12 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at September 13, 2022 15:29 / Updated at September 13, 2022 15:34